EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Long-term clinical and endoscopic outcomes of ulcerative colitis after liver transplantation: a multicenter cohort study on the use and safety of advanced therapies

Ebru Ar iD, Irini Solomonidou iD, Henrike Lenzen iD, Miriam Wiestler iD, Claudia Veltkamp iD, Katharina Willuweit iD, Jassin Rashidi-Alavijeh iD, Hartmut H Schmidt iD, Richard Vollenberg iD, Phil-Robin Tepasse iD, Jonel Trebicka iD, Stefanie Tischendorf iD und 3 weitere

Inflammatory Bowel Diseases · 01.05.2026 · 32 (5) · 945-953

DOI: 10.1093/ibd/izaf330 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 30.01.2026. Verfasst von Ebru Ar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, and Transplant Medicine, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Liver Transplantation, Gastrointestinal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Some patients with ulcerative colitis (UC) develop advanced liver disease due to conditions such as primary sclerosing cholangitis (PSC) and may require liver transplantation (LT). However, data on the long-term course of UC and the use of advanced therapies in LT recipients are limited. We aimed to evaluate UC activity before and after LT, as well as the role of advanced therapies over extended follow-up in this population.

Methods

This was a retrospective, multicenter cohort study including 213 patients with UC who underwent LT between 2000 and 2022. Clinical disease activity (partial Mayo score), endoscopic disease activity (Mayo endoscopic subscore), and the use of advanced therapies were evaluated before and after transplantation.

Results

Among the 213 patients, the clinical remission rate was 84.7% before and 81.2% after LT, showing no significant change (P = .416). Despite stable clinical remission, 27.9% of patients exhibited moderate-to-severe endoscopic inflammation during long-term follow-up (mean: 110 months). The use of advanced therapies increased significantly after LT (from 3.7% to 12.7%, P = .005) and was not associated with an increase in infectious complications (P = .591).

Conclusions

In most patients, clinical disease activity remains stable after LT. However, persistent moderate-to-severe mucosal inflammation is observed in a substantial subset during long-term follow-up. Advanced therapies, particularly vedolizumab, are being used more frequently in this setting and may offer disease control without a corresponding increase in infection risk. These findings underscore the need for individualized, interdisciplinary management and further prospective evaluation of treatment strategies in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeLiver TransplantationGastrointestinal AgentsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedFollow-Up StudiesRemission InductionTreatment OutcomePrognosis

Stichwörter der Autor:innen

advanced therapiesliver transplantationulcerative colitis

Substanzen

Gastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology, and Transplant Medicine, University Hospital Essen, Essen, Germany.
  • Faculty of Medicine, University of Duisburg-Essen, Essen, Germany.
  • Department of Medicine B (Gastroenterology, Hepatology, Endocrinology, Clinical Infectiology), University Hospital Muenster, Muenster, Germany.
  • Department of Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Medical Clinic III, Gastroenterology, Metabolic Diseases, and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany.
  • Department for Gastroenterology, Diabetology, and Palliative Care, Bonifatius Hospital Lingen, 49808 Lingen, Germany.

ORCID-Profile: Ebru Ar, Irini Solomonidou, Henrike Lenzen, Miriam Wiestler, Claudia Veltkamp, Katharina Willuweit, Jassin Rashidi-Alavijeh, Hartmut H Schmidt, Richard Vollenberg, Phil-Robin Tepasse, Jonel Trebicka, Stefanie Tischendorf, Carsten Elfers, Karim Hamesch, Arne Bokemeyer

Zitieren

APA

Ar, E., Solomonidou, I., Lenzen, H., Wiestler, M., Veltkamp, C., Willuweit, K., Rashidi-Alavijeh, J., Schmidt, H. H., Vollenberg, R., Tepasse, P. R., Trebicka, J., Tischendorf, S., Elfers, C., Hamesch, K., & Bokemeyer, A. (2026). Long-term clinical and endoscopic outcomes of ulcerative colitis after liver transplantation: a multicenter cohort study on the use and safety of advanced therapies. Inflammatory Bowel Diseases, 32(5), 945-953. https://doi.org/10.1093/ibd/izaf330

Vancouver

Ar E, Solomonidou I, Lenzen H, Wiestler M, Veltkamp C, Willuweit K, et al. Long-term clinical and endoscopic outcomes of ulcerative colitis after liver transplantation: a multicenter cohort study on the use and safety of advanced therapies. Inflammatory Bowel Diseases. 2026;32(5):945-953. doi:10.1093/ibd/izaf330

BibTeX
@article{Ar2026,
  author = {Ar, Ebru and Solomonidou, Irini and Lenzen, Henrike and Wiestler, Miriam and Veltkamp, Claudia and Willuweit, Katharina and Rashidi-Alavijeh, Jassin and Schmidt, Hartmut H and Vollenberg, Richard and Tepasse, Phil-Robin and Trebicka, Jonel and Tischendorf, Stefanie and Elfers, Carsten and Hamesch, Karim and Bokemeyer, Arne},
  title = {Long-term clinical and endoscopic outcomes of ulcerative colitis after liver transplantation: a multicenter cohort study on the use and safety of advanced therapies},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {5},
  pages = {945--953},
  doi = {10.1093/ibd/izaf330}
}
Kostenlos starten →